MPG.eBooks - Description: CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes

Cover Image

Read Now

CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes

The Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin not be listed for the treatment of type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, April 27, 2016
Series:	Common drug review
Subjects:	Insurance, Health, Reimbursement Sulfonylurea Compounds Drug Combinations Canada Metformin Hypoglycemic Agents / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Drug Costs
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK538386
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin not be listed for the treatment of type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea
Physical Description:	1 PDF file (5 pages)